Recap: DermTech Q2 Earnings

Shares of DermTech DMTK rose in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share fell 1.72% over the past year to ($0.59), which missed the estimate of ($0.53).

Revenue of $3,119,000 higher by 269.55% year over year, which beat the estimate of $2,850,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

DermTech hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Aug 04, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/ftwy8ub7

Technicals

Company's 52-week high was at $84.49

52-week low: $9.85

Price action over last quarter: Up 0.92%

Company Description

DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!